MedPath

effect liqurice in treatment of schizophernia

Phase 2
Conditions
schizophrenia.
Schizophrenia
Registration Number
IRCT20111105008013N2
Lead Sponsor
Ahvaz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
40
Inclusion Criteria

Active schizophrenia
Met DSM-IV criteria for chronic schizophrenia
Drug regimen of risperidone (6 mg/day), cetirizine (4 mg/day)

Exclusion Criteria

Bipolar disorder
Borderline-schizotypal-Antisocial personality disorder
?Eating disorder
Alcohol and drug (other than schizophrenia drugs) abuse in the past month
Suicide or suicidal ideation
History of neurologic and systemic disorders
Thyroid dysfunction
Administration of antidepressants and Anti-anxiety drugs
Steroids (such as oral contraceptives)
Use of MAO-I drugs
Pregnancy and lactation

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Positive symptoms; Negative symptoms; General psychopathological symptoms. Timepoint: Start intervention and a month later. Method of measurement: PANSS score.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath